Alliqua Inc fka ALQA

[Golden Cross]

Bird flu - the "new oil & gas" for investors...
Looking for quick gains?
The bird flu boom could give you 800% or more in just weeks...
Bird flu stocks are skyrocketing.
Top choice: HepaLife Technologies (HPLF).
Less than 45 days ago this undiscovered company picked up patents for the key bird flu vaccine technology.
Amazingly, its share price is still around $1.00. Buy today and you could potentially see gains of 800% or more as it takes off.
Find the next Big Boom and you're almost assured gains like these ... I recognized the energy, semi- conductor, and other booms early on, and look how my subscribers profited:


Hecla Mining Co. 1,108%
Coeur d'Alene 440 %
Xoma Ltd 124 %
Huaneng Power Int. 136 %
OmniVision Technologies 172 %
Newmont Mining 182 %
Pan American Silver Corp. 197 %
Dot Hill Systems Corp. 250 %
Kinross Gold Corp. 339 %
The Bombay Company, Inc. 504 %
Stryker Corp. 525 %
Talk America Holdings, Inc. 853 %
HepaLife Technologies ?????

I'm forecasting HPLF to be my next big gainer!

Ken Coleman
The Investment-Tracker



Kenneth Coleman's Investment-Tracker subscribers are up 52% over the past 5 years. He is a former member of the Senate Select Committee on Federal Reserve Policy, and his show is syndicated nationally on TNN. Mr. Coleman called gold's rise in 2002, as well as the dotcom buying mania from September 1999 to March 2000, and the subsequent meltdown. He also called the kick-off of the world's great bull market in 1982 in a book he wrote in 1981, the bond bull market of 1984, the dollar's plunge during 1984-87, and the rotational market of 1995-98.


Are you looking for a new way to make big dollars in the post oil-boom market? Here's a strategy that savvy short term traders use for big gains.

News drives up share prices. And big news equals big gains. Look at recent history: 9/11 drove up defense and security shares. Hurricane Katrina and other crisis events drove up oil and gas shares. But oil's played out. The avian flu index is up 43.69% so far this year, to oil's 14%.

Bird flu is one of the biggest crisis stories in years. And this is just the beginning. Buy this vaccine developer today and you could potentially be holding the best, most profitable buy you've made in years.

I believe the time is right for HPLF to skyrocket. Here's why...

As news of the global bird flu scare picked up going into last winter's flu season, share prices of vaccine makers skyrocketed. One company shot up more than 800%. Another went from $3.82 to over $22 in about the same time.

In January, after another news surge, a third flu-related company gained more than 120% in 13 days. Yet another zoomed from under $1 to more than $4 in less than 90 days during the same time.

If you think that's impressive, wait till bird flu hits the U.S., as experts think it will sometime this winter. The story will dominate headlines, and HPLF's share prices could skyrocket to astronomical gains. I'm projecting 800% or more, based on what I've already seen in the industry, and the fact that the problem will become worse and the headlines will become louder.

Short term gains for traders,
long term gains for investors
My name is Ken Coleman, publisher and editor of The Investment-Tracker, and I specialize in finding companies that are at the cusp of breakthrough. Companies that rise fast and keep on rising. Short term gains for traders, and long term gains for investors -- the best of both worlds.

Because I know how to recognize trends and the impact of economic changes, I often get the jump on other newsletters and money managers. Here are a few examples:

I found Ultra Petroleum (upl) for my subscribers after news of a natural gas shortage. upl shot up a staggering 4,000%.
I recommended high fashion newcomer True Religion (trlg) after seeing the jeans embraced by celebrities. Some time later TRLG became the darling of Wall Street analysts, but not until investors who followed my recommendation took home around 2,000%.
On signs of dollar weakness I recommended Bema Gold (bgo), which went on to gain more than 500%.
My newest recommendation could be the best one yet. HepaLife is still undiscovered, and on the right side of a major world event: a new vaccine for the killer flu that experts warn is coming our way.

HPLF could gain 800%
or more in the next few months
I'm forecasting 800% gains in the short term. Longer term, the company could have one of the most important health discoveries in recent history. It could be your ticket to wealth. Here's why....

Bird flu is the biggest health danger of our time. More than half of everyone infected has died. Experts say we could be only months from a worldwide pandemic that could kill tens of mil-lions.

Dr. David Nabarro of the World Health Organization says he is "almost certain there will be another pandemic soon." The death toll forecast? From 2 to 7.4 million fatalities. Unless an effective vaccine is found and produced.



H5N1 Outbreaks in 2005 and major flyways of migratory birds.
Situation on 30 August 2005. Shown in red - Districts with H5N1 Outbreaks since January 2005 (Source: www.fao.org)

Governments worldwide are preparing for a global disaster of untold magnitude. Containment relies on having billions of doses of vaccine stockpiled and ready. The problem: There is none.

And so authorities are anxiously awaiting a vaccine that works. A vaccine that is quickly produced and stable in storage. A vaccine like the one being developed by HepaLife Technologies (HPLF).

I've had my eye on HPLF for a while. I've watched their science progress, their company mature. And about 45 days ago, when they picked up the patents for a very promising bird flu vaccine, I knew it was time to buy.

Why? Because,

"You and I are about to see what could be the biggest human disaster in history, and there are only a handful of companies that have the potential to prevent it."
In case you think that's an exaggeration, I've got the facts to prove it.

For starters, just look at the Spanish flu pandemic of 1918. Like today's threat, it started in birds and migrated to humans. It hit every country on earth. Not one was spared. The epidemic sped around the globe in only five months.

When and if bird flu completes its last necessary mutation to jump from birds to humans, think how fast it will travel. Today a plane can circle the earth in less time than a train could cross the continent back then.

In 1918 and 1919 more than 21 million people died. A quarter of the world's population was infected. With more crowded cities, non-stop air travel, and poor hygiene still in many parts of the world, how fast would it travel today? Experts fear it will be only a matter of weeks before it spreads globally.

And don't think that antibiotics will help. Flu is a virus, and antibiotics don't work on viruses. If they did, we wouldn't have flu, and we wouldn't have AIDs anymore either. Viruses are as tough to kill as bacteria was before penicillin.



Caption: Chicken - Convalescent broiler breeder, HPAI, showing detection of type A influenza nucleoprotein antigen in the testicle by IHC staining. (Source: www.fao.org)

A disaster waiting to happen
There are currently only four drugs on the market that can battle even the mildest flu. But the lethal strain known as bird flu, or H5N1, is resistant to even to our best weapon, oseltamivir, branded as Tamiflu.

Even if Tamiflu worked, it would be too little, too late. The product must be stored at below 30 degrees Fahrenheit. That is well beyond the capabilities of the world's third world countries where the disease would spread far and fast.

What's more, all of the flu vaccines are made by a broken down system that's a disaster waiting to happen. The vaccines are made by harvesting viruses in chicken eggs. But the bird flu virus is as deadly to the eggs as it is to the chickens. And so the virus must first be deactivated by altering its genetic code.

The whole process can take up to six months. And that's supposing that the bird flu hasn't already wiped out the billions of chickens necessary to produce the eggs to produce the virus.

Clearly, this needs to change!
The only hope is a new method of vaccine production, like HepaLife's
I have discovered 17 companies that are developing bird flu vaccines. The one that produces the most effective product could potentially walk away with one of the largest first-year sa1es in pharmaceutical history.

Health agencies around the world are chomping at the bit for their vaccine product. The U.S. has earmarked $3.9 billion to buy vaccines. The figurative purchase orders are already written. The only problem: Who to send them to.

I've looked at each of the companies, and have concluded that HepaLife Technologies (HPLF) has the most promising technology.

Your Number One Buy Today:
HepaLife Technologies, Inc. (HPLF)
HepaLife has several big advantages over other companies developing flu vaccines. First of all is the technology itself.

Instead of the problem-ridden egg culture production method, HPLF's patented technology relies on a totally new and improved method. It is the first immortal chicken embryo cell line that is virus-free and contact-inhibited.

That means that the cells grow continuously, instead of needing to be introduced into a host egg every time the vaccine is produced. There is less risk of foreign contaminants such as Salmonella, Newcastle disease, or reovirus that frequently plague current production methods. It also allows a more rapid response to new influenza strains that might arise or become a threat. An additional advantage is that individuals with allergies to eggs, who cannot be vacinnated with current vaccines, could receive a cell culture based product.

The result...

Lower production costs
Faster production time
Less risk of vaccine contamination
Less risk of allergic reaction
Another big advantage for HepaLife is that it is one of the new breed of "virtual" companies.

In today's high-cost environment, the smartest companies are reducing overhead and speeding time to market by subcontracting everything from product development to production.

What it means to you is that HPLF has just a fraction of the costs that burden many a company's cost to earnings ratios. That lowers the company's risk by a huge degree. And so it lowers your risk as well.

HepaLife Technologies (HPLF) could give 800% returns within 8-12 weeks when bird flu hits the headlines again
Let's take a look at the facts for HPLF again:

HPLF just entered the bird flu vaccine market. Investors haven't discovered it yet and share price is still about $1
HPLF has the one of the most advanced technologies for vaccine production, protected by five patents
Shares in crisis-boom companies rise on headlines. Bird flu headlines are becoming more pressing, more frequent
I expect HPLF to skyrocket as soon as the next phase of the bird flu scare hits and investors discover the company
Short term gains could be 800% or more for HPLF
But here's the kicker....

HepaLife's vaccine technology is so breakthrough, so important that longterm, HPLF could potentially be one of the most profitable investments of your life.

Increase your chance for 800% returns with HPLF
I'm a conservative investor. Most of the recommendations I give my Investment-Tracker subscribers are conservative. But I also have a portfolio of "incubating-stocks" that consists of small companies with big potential.

Companies like these, which I discovered before their big run-ups....

Company Returns
Hecla Mining Co. 1,108%
Coeur d'Alene 439.83%
Xoma Ltd 124%
Huaneng Power Int. 136.05%
OmniVision Technologies 172.19%
Newmont Mining 183.49%
Pan American Silver Corp. 196.5%
Dot Hill Systems Corp. 250.35%
Kinross Gold Corp. 339.46%
The Bombay Company, Inc. 504%
Stryker Corp. 525.19%
Talk America Holdings, Inc. 853%

I believe HPLF will make that list of big gains for my subscribers, and for you. Other bird flu stocks have seen big gains in just the past few months. HPLF is a new entry in that market, with what I see as a better technology, a better company profile, and even better chances for both long and short term gains.

Consider adding HPLF to your portfolio today.

For your convenience below you'll see links to some of the most popular online brokerages:

ameritrade.com
etrade.com
sharebuilder.com
schwab.com
scottrade.com
optionsxpress.com

Here's to your successful investing!

Sincerely,

Ken Coleman
Publisher & Editor, The Investment-Tracker


Would you like more picks like:
HL (up 1,108%),
TALK (up 525.19%)
and HPLF (projected 800%)?
Read The Investment-Tracker Today!
The Investment-Tracker


Disclaimer: Kenneth Coleman's Investment Tracker is an independent paid circulation newsletter. This online report is an advertisement for subscriptions. The Investment Tracker's goal is to give the investor the necessary knowledge to make rational and profitable investment decisions. The Investment Tracker received no compensation with respect to the writing of this special report, however, the Investment Tracker expects to generate new subscriber revenue, the amount of which is unknown at this time, to its newsletter through the distribution of this special report. Compensation associated with distribution to possible new subscribers in the amount of $6,000 was paid for by Jeslyn Capital Corporation, an independent investor relations agency, as an effort to build investor awareness for HepaLife Technologies, Inc. This publication does not provide an analysis of a company's financial position and is not an offer to buy or sell securities. HepaLife's financial position and all information should be verified with the company. HepaLife currently has no commercial products intended to diagnose, treat, prevent or cure any disease. Information about publicly listed companies, including HepaLife, and other investor resources can be found at the Securities & Exchange Commission website http://www.sec.gov/. Investing in securities is speculative and carries a high degree of risk. It is recommended any investment in any security should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Jeslyn Capital Corporation, its employees and affiliates and Kenneth Coleman and the Investment Tracker are not investment advisors and are not affiliated with each other, either directly or indirectly. The Investment Tracker presents information in this report believed to be reliable, but its accuracy cannot be guaranteed. Past performance does not guarantee future results. The information contained herein contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company. In accordance with safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect actual results of operations. Factors that could cause actual results to differ materially include, but are not limited to, adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other specific risks detailed in HepaLife's filings with the Securities and Exchange Commission on Form 10-K and 10-Q. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should or might occur. The Investment Tracker undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

HepaLife Technologies Inc.
60 State Street, Suite 700
Boston, Massachusetts 02109

To unsubscribe please click here: http://hepalife.com/optout.php